The Consumer Electronics Show has become an early-year trend barometer for health tech, and this year was no different as immersive tech took center stage at the annual Las Vegas event.
Are today’s developmental drugs tomorrow’s blockbusters? We survey what’s ahead for top candidates in six therapeutic categories.
With less than 14% of Phase I to III drug candidates winning FDA approval, unforeseen roadblocks can derail even the most promising clinical research programs.
Two touted products in the pipeline reflect three of medical marketing’s most profound modern-era challenges.
With pharma facing ongoing scrutiny of its pricing practices, medical marketers are increasingly asked to demonstrate the superior value of new therapies. High-profile candidates in immunology, pain management, and melanoma challenge marketers well in advance of launch.
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.